Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Hold” from Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has earned an average rating of “Hold” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $23.75.

Several research firms have issued reports on DAWN. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Friday, March 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. JonesTrading cut shares of Day One Biopharmaceuticals from a “buy” rating to a “hold” rating and raised their target price for the stock from $20.00 to $21.50 in a report on Friday, March 6th. Zacks Research downgraded shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Wedbush reiterated a “neutral” rating and set a $21.50 target price (down from $30.00) on shares of Day One Biopharmaceuticals in a research note on Monday, March 9th.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 15,459 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $179,324.40. Following the transaction, the chief executive officer directly owned 204,603 shares of the company’s stock, valued at approximately $2,373,394.80. This trade represents a 7.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Adam Dubow sold 6,395 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $74,182.00. Following the completion of the transaction, the insider directly owned 72,694 shares in the company, valued at $843,250.40. The trade was a 8.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 36,461 shares of company stock valued at $422,948 over the last ninety days. 6.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently made changes to their positions in the business. AIGH Capital Management LLC purchased a new stake in Day One Biopharmaceuticals during the third quarter valued at approximately $10,719,000. AlphaQuest LLC boosted its stake in shares of Day One Biopharmaceuticals by 1,065.6% during the 3rd quarter. AlphaQuest LLC now owns 185,006 shares of the company’s stock worth $1,304,000 after acquiring an additional 169,134 shares during the last quarter. Schroder Investment Management Group purchased a new position in shares of Day One Biopharmaceuticals during the 2nd quarter worth $1,171,000. Mak Capital One LLC bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at $10,212,000. Finally, Geode Capital Management LLC grew its position in shares of Day One Biopharmaceuticals by 11.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company’s stock valued at $11,132,000 after acquiring an additional 171,964 shares during the period. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Up 0.2%

Shares of DAWN opened at $21.44 on Wednesday. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -20.82 and a beta of -1.25. The business’s fifty day simple moving average is $13.55 and its two-hundred day simple moving average is $10.06. Day One Biopharmaceuticals has a 12 month low of $5.64 and a 12 month high of $21.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The business had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million. As a group, research analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.